Beraprost
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Beraprost
| |
| Systematic (IUPAC) name | |
| 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4- methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran- 5-butanoic acid | |
| Identifiers | |
| CAS number | 88475-69-8 (sodium salt) |
| ATC code | B01 |
| PubChem | |
| Chemical data | |
| Formula | C24H30O5 |
| Mol. mass | 398.492 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 50–70% |
| Metabolism | Unknown |
| Half life | 35–40 minutes |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
? |
| Routes | Oral |
|
WikiDoc Resources for Beraprost | |
|
Articles | |
|---|---|
|
Most recent articles on Beraprost | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Beraprost at Clinical Trials.gov Clinical Trials on Beraprost at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Beraprost
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Beraprost Discussion groups on Beraprost Directions to Hospitals Treating Beraprost Risk calculators and risk factors for Beraprost
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Beraprost | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.
Clinical pharmacology
As an analogue of prostacyclin PGI2, beraprost effects vasodilation, which in turn lowers the blood pressure. Beraprost also inhibits platelet aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.
Dosage and administration
Beraprost is administered orally as a pill.
Medications used in the management of pulmonary arterial hypertension (B01, C02) | |
|---|---|
| Prostacyclin analogues | Beraprost, Epoprostenol, Iloprost, Treprostinil |
| Endothelin receptor antagonists | Ambrisentan, Bosentan, Sitaxsentan |
| PDE5 inhibitors | Sildenafil, Tadalafil |
| Adjunctive therapy | Calcium channel blockers, Diuretics, Digoxin, Oxygen therapy, Warfarin |
Eicosanoids: prostaglandins | |
|---|---|
| Endogenous/series 2 | D2 - E2 (Dinoprostone) - F2 (Dinoprost) - H2 - I2 (Prostacyclin) |
| Prostaglandin analogues | E: Alprostadil - Enprostil - Misoprostol
F: Bimatoprost - Carboprost - Latanoprost - Travoprost I: Beraprost - Iloprost - Treprostinil |
WikiDoc Research Resources for Beraprost | |
|---|---|
| Articles on Beraprost | Most recent articles on Beraprost • Most cited articles on Beraprost • Review articles on Beraprost • Articles on Beraprost in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Beraprost | Powerpoint slides on Beraprost • Images of Beraprost • Photos of Beraprost • Podcasts & MP3s on Beraprost • Videos on Beraprost |
| Evidence Based Medicine Regarding Beraprost | Cochrane Collaboration on Beraprost • Bandolier on Beraprost • TRIP on Beraprost |
| Cost Effectiveness of Beraprost | Cost Effectiveness of Beraprost |
| Clinical Trials Involving Beraprost | Ongoing Trials on Beraprost at Clinical Trials.gov • Trial results on Beraprost • Clinical Trials on Beraprost at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Beraprost | US National Guidelines Clearinghouse on Beraprost • NICE Guidance on Beraprost • NHS PRODIGY Guidance • FDA on Beraprost • CDC on Beraprost |
| Textbook Information on Beraprost | Books and Textbook Information on Beraprost |
| Pharmacology Resources on Beraprost | Dosing of Beraprost • Drug interactions with Beraprost • Side effects of Beraprost • Allergic reactions to Beraprost • Overdose information on Beraprost • Carcinogenicity information on Beraprost • Beraprost in pregnancy • Pharmacokinetics of Beraprost • |
| Genetics, Pharmacogenomics, and Proteinomics of Beraprost | Genetics of Beraprost • Pharmacogenomics of Beraprost • Proteomics of Beraprost |
| Newstories on Beraprost | Beraprost in the news • Be alerted to news on Beraprost • News trends on Beraprost |
| Commentary on Beraprost | Blogs on Beraprost |
| Patient Resources on Beraprost | Patient resources on Beraprost • Discussion groups on Beraprost • Patient Handouts on Beraprost • Directions to Hospitals Treating Beraprost • Risk calculators and risk factors for Beraprost |
| Healthcare Provider Resources on Beraprost | Symptoms of Beraprost • Causes & Risk Factors for Beraprost • Diagnostic studies for Beraprost • Treatment of Beraprost |
| Continuing Medical Education (CME) Programs on Beraprost | CME Programs on Beraprost |
| International Resources on Beraprost | Beraprost en Espanol • Beraprost en Francais |
| Business Resources on Beraprost | Beraprost in the Marketplace • Patents on Beraprost |
| Informatics Resources on Beraprost | List of terms related to Beraprost |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
